U.S. hospitals have been slow to embrace Covid-19 antibody drugs from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that were authorized to reduce the risk of hospitalization, U.S. officials said.
New York-based TG Therapeutics announced positive topline results from two global Phase III clinical trials, ULTIMATE I and II, of ublituximab in relapsing forms of multiple sclerosis (RMS).
The U.S. Food and Drug Administration approved Janssen’s Simponi Aria (golimumab) for patients 2 years of age and older for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) and extended the medicine’s active psoriatic arthritis (PsA) indication for this same patient population.
Option Care Health Inc., the largest U.S. independent provider of home and alternate site infusion services, was selected to participate in the limited distribution network of VILTEPSO (viltolarsen) for patients with Duchenne Muscular Dystrophy who are amenable to exon 53 skipping therapy.
Gilead Sciences Inc., maker of the closely watched experimental coronavirus drug remdesivir, said the company will work with international partners to expand production of the potential COVID-19 treatment.
Melbourne, Australia and New York-based Mesoblast Limited announced that in a study of COVID-19 patients with moderate to severe acute respiratory distress syndrome, there was 83 percent survival with two intravenous infusions of the company’s experimental allogeneic mesenchymal stem cell candidate Ryoncil (remestemcel-L).
Denmark’s Lundbeck agreed to buy Alder BioPharmaceuticals in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.
Baxter International Inc. announced the U.S. Food and Drug Administration approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection).
Pfizer Inc. said the company received grand jury subpoenas from the U.S. Justice Department amid an antitrust investigation focused on drugmakers that market intravenous saline solution.
Pfizer announced that the company is planning to sell its current world headquarters building in midtown Manhattan.